Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase

Biochemical Pharmacology

Volumn 54, Issue 6, 1997, Pages 649-655

  Rappa, Germana ^a   Lorico, Aurelio ^a   Liu, Mao Chin ^a   Kruh, Gary D ^b   Cory, Ann H ^c   Cory, Joseph G ^c   Sartorelli, Alan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

3 AP; Gene knockout; L1210 leukemia; Multidrug resistance; Ribonucleotide reductase

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; RIBONUCLEOTIDE REDUCTASE; THIOSEMICARBAZONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG TRANSPORT; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA L 1210; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; LEUKEMIA L1210; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; RIBONUCLEOTIDE REDUCTASES; THIOSEMICARBAZONES;

EID: 0030869671     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00210-4     Document Type: Article

References (27)

1. Cory JG, Role of ribonucleotide reductase in cell division. In: Inhibitors of Ribonucleoside Diphosphate Reductase Activity, International Encyclopedia of Pharmacology and Therapeutics (Eds. Cory JG and Cory AH), Section 128, pp. 1-16. Pergamon Press, New York, 1989.
2. Krakoff IH, Clinical and pharmacological effects of hydroxyurea. In: Antineoplastic and Immunosuppressive Agents, Part II (Eds. Sartorelli AC and Johns DG), pp. 789-792. Springer, New York, 1975.
3. Brockman RW, Thompson JR, Bell MJ and Skipper HE, Observations on the antileukemia activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res 16: 167-170, 1956.
4. Sartorelli AC, Agrawal KC, Tsiftsoglou AS and Moore EC, Characterization of the biochemical mechanism of action of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv Enzyme Regul 15: 117-139, 1977.
5. Liu M-C, Lin T-S and Sartorelli AC, Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 35: 3672-3677, 1992.
6. Creasey WA, Agrawal KC, Capizzi RL, Stinson KK and Sartorelli AC, Studies of the antineoplastic activity and metabolism of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice. Cancer Res 32: 565-572, 1972.
7. DeConti RC, Toftness BR, Agrawal KC, Tomchik R, Mead JAR, Bertino JR, Sartorelli AC and Creasey WA, Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res 32: 1455-1462, 1972.
8. Cory JG, Cory AH, Rappa G, Lorico A, Liu M-C, Lin T-S and Sartorelli AC, Inhibitors of ribonucleotide reductase: Comparative effects of amino-and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 48: 335-344, 1994.
9. Cory JG, Cory AH, Rappa G, Lorico A, Liu M-C, Lin T-S and Sartorelli AC, Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv Enzyme Regul 35: 55-68, 1995.
10. Beck WT, The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879-2887, 1987.
11. Endicott JA and Ling V, The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 131-171, 1989.
12. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L, Mol CAAM, Ottenhoff R, van der Lugt NMT, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM and Borst P, Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462, 1993.
13. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EGE, Baas F and Borst P, Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750, 1993.
14. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
15. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG, Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994.
16. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA and Kruh GD, Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55: 5342-5347, 1995.
17. Lorico A, Rappa G, Flavell RA and Sartorelli AC, Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res 56: 5351-5355, 1996.
18. Cory AH, Sato AS, Thompson DP and Cory JG, Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-araino-1-formylisoquinoline thiosemicarbazone. Oncol Res 8: 449-456, 1996.
19. Cory AH, Owen TC, Barltrop JA and Cory JG, Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212, 1991.
20. Ueda K, Cardarelli C, Gottesman MM and Pastan I, Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008, 1987.
21. Yang JM and Hait WN, Use of multidrug resistant L1210 cell line for in vitro and in vivo drug screening. Proc Am Assoc Cancer Res 32: 364, 1991.
22. Paul S, Breuninger LM, Tew KD, Shen H and Kruh GD, ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc Natl Acad Sci USA 93: 6929-6934, 1996.
23. Schmid I, Schmid P and Giorgi J, Conversion of logarithmic channel numbers into relative linear fluorescence intensity. Cyometry 1: 533-538, 1988.
24. Rappa G, Lorico A and Sartorelli AC, Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Cancer Res 53: 5487-5493, 1993.
25. Darnowski JW, Holdridge C and Handschumacher RE, Concentrative uridine transport by murine splenocytes: Kinetics, substrate specificity, and sodium dependency. Cancer Res 47: 2614-2619, 1987.
26. Chomczynski P and Sacchi N, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
27. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SPC and Sehested M, Sequential coexpression of the multidrug resistance genes MRP and mdrl and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55: 459-462, 1995.